November 20, 2017
1 min read

Arthroscopic glenoid resurfacing with allograft seen as safe for joint preservation in select patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

At the short-term to midterm follow-up, investigators found arthroscopic glenoid resurfacing with an interpositional human dermal allograft was a safe option that offered pain relief in select patients and the rate of revision to prosthetic arthroplasty was acceptable.

Robert U. Hartzler

“Our study revealed that for patients with severe arthritis who are poor candidates for a shoulder replacement (usually young and active), an all-arthroscopic, joint-preserving surgical option exists that can provide good pain relief comparable to a total shoulder,” study co-author Robert U. Hartzler, MD, told “With this arthroscopic interpositional arthroplasty, about three-fourths of our patients were able to avoid a shoulder replacement at average 5-year follow-up.”

Researchers performed a multicenter retrospective review of 46 shoulders in 45 patients who underwent arthroscopic glenoid resurfacing for severe glenohumeral arthritis. The minimum follow-up was 2 years or until revision. Outcome measures included pain score, American Shoulder and Elbow Surgeons score, subjective shoulder value and range of motion.

Results showed after a mean of 45 months, the revision rate to prosthetic arthroplasty was 23%. Investigators noted VAS pain score went from a median of 7 to 2. There were improvements seen in the median ASES score, active forward elevation and active external rotation.

According to researchers, the mean age of revised shoulders was higher than the age of the surviving shoulders. The revised shoulders vs. the surviving shoulders had a lower preoperative ASES score. There were no complications reported. – by Monica Jaramillo


Disclosures: The authors report no relevant financial disclosures.